ACUTE CORONARY SYNDROME DAN PENGGUNAAN STATIN

SLIDE INI MENJELASKAN MENGENAI HUBUNGAN ANTARA ACUTE CORONARY SYNDROME DAN PENGGUNAAN STATIN. DAPAT DIBACA JUGA DI NEJM

1. Intensive versus Moderate Lipid Lowering with
Statins after Acute Coronary Syndromes
Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S.,
Daniel J. Rader, M.D., Jean L. Rouleau, M.D., Rene Belder, M.D., Steven V. Joyal,
M.D., Karen A. Hill, B.A., Marc A. Pfeffer, M.D., Ph.D., Allan M. Skene, Ph.D. and the
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators
N Engl J Med
Volume 350;15:1495-1504
April 8, 2004

2. Study Overview
•This study compared moderate lipid lowering with pravastatin and
intensive lipid lowering with atorvastatin in patients after an acute
coronary syndrome
•Over a mean follow-up period of two years, those treated with the
intensive lipid-lowering regimen had better outcomes
•The findings add to a growing body of evidence supporting the use of
intensive lipid lowering to prevent cardiovascular events
•The current recommended target levels for low-density lipoprotein
cholesterol in persons at risk may need to be lowered

3. Base-Line Characteristics of the Patients
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

4. Median Low-Density Lipoprotein (LDL) Cholesterol Levels during the Study
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

5. Kaplan-Meier Estimates of the Incidence of the Primary End Point of Death from Any Cause or a
Major Cardiovascular Event
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

6. Hazard Ratio for the the Primary End Point of Death from Any Cause or a Major Cardiovascular
Event at 30, 90, and 180 Days and at the End of Follow-up in the High-Dose Atorvastatin Group,
as Compared with the Standard-Dose Pravastatin Group
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

7. Estimates of the Hazard Ratio for the Secondary End Points and the Individual Components of
the Primary End Point in the High-Dose Atorvastatin Group, as Compared with the Standard-
Dose Pravastatin Group
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

8. Two-Year Event Rates and Estimates of the Hazard Ratio for the Primary End Point in the High-
Dose Atorvastatin Group, as Compared with the Standard-Dose Pravastatin Group, According to
Base-Line Characteristics
Cannon, C. et al. N Engl J Med 2004;350:1495-1504

9. Conclusions
•Among patients who have recently had an acute coronary syndrome, an
intensive lipid-lowering statin regimen provides greater protection
against death or major cardiovascular events than does a standard
regimen
•These findings indicate that such patients benefit from early and
continued lowering of LDL cholesterol to levels substantially below
current target levels